Notificação de acontecimentos adversos ou reclamações de qualidade
AZ Medical Global

Áreas Terapêuticas
Medicamentos
Recursos
Conectar

Login

Search Medical Information

Para pesquisar informação científica, deverá especificar pelo menos dois termos de pesquisa

Search Medical Information

World Conference on Lung Cancer (WCLC) 2025

September 06 - 09, 2025

Datopotmab deruxtecan
Durvalumab
Osimertinib
Rilvegostomig
Savolitinib
Trastuzumab Deruxtecan
Volrustomig

ppt

Intracranial Efficacy of Datopotamab Deruxtecan (Dato DXd) in Patients With Advanced/metastatic NSCLC in TROPION-Lung01

ppt

Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN

ppt

Detection of ctDNA Prior to Neoadjuvant Osimertinib Treatment Correlates With Decreased EFS in EGFR-Mutated NSCLC

ppt

Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study

pdf

Treatment Patterns and Clinical Outcomes in South Korean Patients With Unresectable Stage III EGFRm NSCLC Undergoing CRT

pdf

Stereotactic Body Radiation Therapy for Medically Inoperable Stage I/II EGFRm NSCLC: Global, Multicenter, Retrospective Study

pdf

Real-World (RW) Study of Biomarker Testing Patterns Among Patients With Early-Stage Resected NSCLC in the United States

ppt

First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival

ppt

First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype

ppt

First-Line Osimertinib ± Platinum-Pemetrexed Chemotherapy for EGFR-Mutated Advanced NSCLC: FLAURA2 Non-Asian Country Cohort

ppt

COMPEL: Osimertinib + Platinum-Based Chemotherapy in Patients With EGFRm Advanced NSCLC and Progression on 1L Osimertinib

pdf

A Phase 3, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment of Patients with Metastatic Squamous Non-small-cell Lung Cancer Whose Tumors Express PD-L1

ppt

Rilvegostomig enhances ex vivo immune activation of patient resected NSCLC tumors to greater levels than clinically approved PDx monotherapies or combinations of anti-PD1 and anti-TIGIT bivalent antibodies

ppt

Osimertinib + Savolitinib in EGFRm Advanced NSCLC With MET Overexp And/Or Amp Post-Progression on Osimertinib: SAVANNAH PROs

ppt

SAVANNAH: Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and / or Amp NSCLC

ppt

Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation Egfr-TKI Failure: SACHI Study Insights

ppt

Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy

pdf

Trastuzumab Deruxtecan in Chinese Patients With Pretreated HER2-mutant Non-small cell Lung Cancer: DESTINY-Lung05 Results

pdf

Trastuzumab Deruxtecan + Pembrolizumab as First-line Treatment in HER2-overexpressing, PD-L1 TPS <50% NSCLC (DESTINY-Lung06)

pdf

Concordance of HER2 Protein Overexpression by IHC and ERBB2 Gene Amplification by NGS in Lung Cancer

pdf

Phase 3 eVOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC with PD-L1 TC <50%

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão

A informação incluída neste website é dirigida exclusivamente a profissionais de saúde.

©2024 AstraZeneca. Todos os direitos reservados. PT-19636

Aprovado a 12/2024.

Sobre o AZMedical

AstraZeneca Portugal

Inquérito de Satisfação

Política de Privacidade

Aviso Legal e Termos de Utilização

Notificação de acontecimentos adversos ou reclamações de qualidade

Política de Privacidade

Aviso Legal e Termos de Utilização